Home > Boards > US OTC > Delisted > Synergy Pharmaceuticals Inc. (fka SGYPQ)

If you've read every SGYPQ PR, SEC Filing,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Polack Member Profile
 
Followed By 0
Posts 161
Boards Moderated 0
Alias Born 07/28/07
160x600 placeholder
Polack   Sunday, 03/10/19 05:58:47 PM
Re: None
Post # of 4272 
If you've read every SGYPQ PR, SEC Filing, and Court Doc, you know that only Trulance/Dolcanatide ("certain assets") were sold to Bausch. Assets SGYPQ retained to develop a new pipeline from are the Uroguanylin GI Platform and "Novel Guanylate Cyclase C Agonists" from patents 10,118,946 & 9,708,367:
"Detailed Description: The present invention is based upon the development of novel agonists of guanylate cyclase-C (GC-C). The agonists are plecanatide derivatives, analogs of uroguanylin, guanylin, lymphoguanylin and ST peptide and have superior properties such as higher activity or potency."
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=novel+guanylate+cyclase+C+%28GC-C%29+agonists&FIELD1=&co1=AND&TERM2=Synergy+Pharmaceuticals&FIELD2=&d=PTXT

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist